185 related articles for article (PubMed ID: 33542854)
1. Gilteritinib: A Novel FLT3 Inhibitor for Relapsed/Refractory Acute Myeloid Leukemia.
Marjoncu D; Andrick B
J Adv Pract Oncol; 2020; 11(1):104-108. PubMed ID: 33542854
[TBL] [Abstract][Full Text] [Related]
2. The European Medicines Agency Review of Gilteritinib (Xospata) for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with an FLT3 Mutation.
Tzogani K; Røshol H; Olsen HH; Aas IB; Dalhus ML; Håkonsen GD; Nilssen LS; Lindberg V; Økvist M; Bolstad B; Rogovska I; Karpova N; Enzmann H; Gisselbrecht C; Pignatti F
Oncologist; 2020 Jul; 25(7):e1070-e1076. PubMed ID: 32154636
[TBL] [Abstract][Full Text] [Related]
3. Gilteritinib for the treatment of relapsed and/or refractory FLT3-mutated acute myeloid leukemia.
McMahon CM; Perl AE
Expert Rev Clin Pharmacol; 2019 Sep; 12(9):841-849. PubMed ID: 31454267
[No Abstract] [Full Text] [Related]
4. Gilteritinib in the treatment of relapsed and refractory acute myeloid leukemia with a FLT3 mutation.
Chew S; Mackey MC; Jabbour E
Ther Adv Hematol; 2020; 11():2040620720930614. PubMed ID: 32547718
[TBL] [Abstract][Full Text] [Related]
5. [Pharmacological and clinical profile of gilteritinib (Xospata
Mori M; Hidaka K
Nihon Yakurigaku Zasshi; 2021; 156(1):37-46. PubMed ID: 33390479
[TBL] [Abstract][Full Text] [Related]
6. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study.
Perl AE; Altman JK; Cortes J; Smith C; Litzow M; Baer MR; Claxton D; Erba HP; Gill S; Goldberg S; Jurcic JG; Larson RA; Liu C; Ritchie E; Schiller G; Spira AI; Strickland SA; Tibes R; Ustun C; Wang ES; Stuart R; Röllig C; Neubauer A; Martinelli G; Bahceci E; Levis M
Lancet Oncol; 2017 Aug; 18(8):1061-1075. PubMed ID: 28645776
[TBL] [Abstract][Full Text] [Related]
7. Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia.
Zhao J; Song Y; Liu D
Biomark Res; 2019; 7():19. PubMed ID: 31528345
[TBL] [Abstract][Full Text] [Related]
8. A budget impact analysis of gilteritinib for the treatment of relapsed or refractory
Pandya BJ; Yang H; Schmeichel C; Qi CZ; Shah MV
J Med Econ; 2021; 24(1):19-28. PubMed ID: 33280474
[TBL] [Abstract][Full Text] [Related]
9. Gilteritinib: First Global Approval.
Dhillon S
Drugs; 2019 Feb; 79(3):331-339. PubMed ID: 30721452
[TBL] [Abstract][Full Text] [Related]
10. Gilteritinib versus chemotherapy in Japanese patients with FLT3-mutated relapsed/refractory acute myeloid leukemia.
Hosono N; Yokoyama H; Aotsuka N; Ando K; Iida H; Ishikawa T; Usuki K; Onozawa M; Kizaki M; Kubo K; Kuroda J; Kobayashi Y; Shimizu T; Chiba S; Nara M; Hata T; Hidaka M; Fujiwara SI; Maeda Y; Morita Y; Kusano M; Lu Q; Miyawaki S; Berrak E; Hasabou N; Naoe T
Int J Clin Oncol; 2021 Nov; 26(11):2131-2141. PubMed ID: 34363558
[TBL] [Abstract][Full Text] [Related]
11. [Gilteritinib for pediatric FLT3 internal tandem duplication-positive recurrent acute myeloid leukemia].
Fukuoka K; Tsumura Y; Noguchi J; Sugawa M; Takaki T; Hiraki T; Inoue K; Mitani Y; Tomita O; Oshima K; Yanagi M; Isobe K; Mori M; Arakawa Y; Koh K
Rinsho Ketsueki; 2020; 61(4):322-326. PubMed ID: 32378574
[TBL] [Abstract][Full Text] [Related]
12. Clinical considerations for the use of FLT3 inhibitors in acute myeloid leukemia.
Weis TM; Marini BL; Bixby DL; Perissinotti AJ
Crit Rev Oncol Hematol; 2019 Sep; 141():125-138. PubMed ID: 31279288
[TBL] [Abstract][Full Text] [Related]
13. Gilteritinib: An FMS-like tyrosine kinase 3/AXL tyrosine kinase inhibitor for the treatment of relapsed or refractory acute myeloid leukemia patients.
Reed DR; Sen JM; Pierce EJ; Elsarrag RZ; K Keng M
J Oncol Pharm Pract; 2020 Jul; 26(5):1200-1212. PubMed ID: 32338136
[TBL] [Abstract][Full Text] [Related]
14. Advancing treatment of acute myeloid leukemia: the future of FLT3 inhibitors.
Elshoury A; Przespolewski A; Baron J; Wang ES
Expert Rev Anticancer Ther; 2019 Mar; 19(3):273-286. PubMed ID: 30681373
[TBL] [Abstract][Full Text] [Related]
15. Gilteritinib in peritransplant period for relapsed or refractory FLT3-mutated acute myeloid leukemia: A case report of three patients.
Mima F; Fuji S; Shibata K; Kida S; Tsutsumi K; Tada Y; Shingai Y; Yuda S; Yokota T; Ishikawa J
Blood Cell Ther; 2023 Aug; 6(3):77-79. PubMed ID: 38146352
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of gilteritinib in combination with chemotherapy in preclinical models of
Ueno Y; Mori M; Kamiyama Y; Saito R; Kaneko N; Isshiki E; Kuromitsu S; Takeuchi M
Oncotarget; 2019 Apr; 10(26):2530-2545. PubMed ID: 31069015
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic Management of Patients with FLT3 + Acute Myeloid Leukemia: Case Reports and Focus on Gilteritinib Monotherapy.
Bocchia M; Carella AM; Mulè A; Rizzo L; Turrini M; Abbenante MC; Cairoli R; Calafiore V; Defina M; Gardellini A; Luzi G; Patti C; Pinazzi MB; Riva M; Rossi G; Sammartano V; Rigacci L
Pharmgenomics Pers Med; 2022; 15():393-407. PubMed ID: 35496349
[TBL] [Abstract][Full Text] [Related]
18. Gilteritinib: A Review in Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukaemia.
Kang C; Blair HA
Target Oncol; 2020 Oct; 15(5):681-689. PubMed ID: 32940858
[TBL] [Abstract][Full Text] [Related]
19. Profile of Quizartinib for the Treatment of Adult Patients with Relapsed/Refractory FLT3-ITD-Positive Acute Myeloid Leukemia: Evidence to Date.
Fletcher L; Joshi SK; Traer E
Cancer Manag Res; 2020; 12():151-163. PubMed ID: 32021432
[TBL] [Abstract][Full Text] [Related]
20. Megakaryocytic Expansion in Gilteritinib-Treated Acute Myeloid Leukemia Patients Is Associated With AXL Inhibition.
Suknuntha K; Choi YJ; Jung HS; Majumder A; Shah S; Slukvin I; Ranheim EA
Front Oncol; 2020; 10():585151. PubMed ID: 33363015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
